Human Genome Editing: Navigating Public Opinion and Scientific Frontiers
"Understanding U.S. attitudes and the call for public engagement in the age of CRISPR."
The advent of CRISPR-Cas9 technology has sparked urgent discussions about human genome editing and its vast applications. Scientists and ethicists alike are advocating for open public dialogue to shape policies and regulations surrounding this groundbreaking technology. A recent consensus report by the U.S. National Academy of Sciences (NAS) and the National Academy of Medicine (NAM) emphasized the importance of incorporating public engagement into the policy-making process.
However, a crucial question remains: What are the current public attitudes toward human genome editing? And how do these sentiments influence the desire for public input as new applications emerge? The NAS/NAM report categorizes genome editing applications based on purpose (therapeutic vs. enhancement) and heritability (somatic vs. germline edits).
While the report provides a framework for permissibility, understanding public attitudes toward these distinctions is crucial. This article explores U.S. public opinions on human genome editing, examining the nuances between therapeutic and enhancement applications, somatic and germline edits, and the overall implications for policy and public engagement.
CRISPR’s Reach and Measured Scale
CRISPR technology is described as revolutionizing biosciences, even though it is not widely recognized by the public, according to Statista. A January 2026 report estimates the global CRISPR genome-editing market could reach approximately $33 billion by 2033. A separate 2026 registry analysis reports examining 144 therapy-grade genome-editing clinical trials, including phase distributions, sponsors, base and prime editing, and in vivo CRISPR catalysts.
From Early Gene Editing to CRISPR
Genome-editing efforts predate CRISPR: the first attempts to edit genes occurred in the 1980s, followed by efforts to develop methods for targeting specific genes. A historical review traces the development of platforms from meganuclease-mediated double-strand breaks and enhanced foreign-DNA integration to CRISPR/Cas9 and re-engineered variants. The CRISPR-Cas microbial adaptive immune system was developed into a genome-editing tool through contributions from scientists around the world. The CRISPR–Cas9 genome-editing method was recognized with the 2020 Nobel Prize in Chemistry, less than a decade after discovery of the system’s principal molecular components.
Decoding Public Acceptance: Therapy vs. Enhancement
Initial insights from a 2016 STAT-Harvard survey revealed that only 35% of U.S. citizens supported therapeutic treatment of unborn babies using gene editing, and a Pew Research Center poll indicated that only 31% of Americans were comfortable with therapies that altered a baby's genetic makeup. These findings highlight the public's cautious approach to genome editing, particularly when it involves altering the genetic code.
- Somatic Therapy: 64% of respondents found somatic therapy acceptable.
- Germline Therapy: 65% of respondents found germline therapy acceptable.
- Somatic Enhancement: 39% of respondents found somatic enhancement acceptable, with 35% finding it unacceptable.
- Germline Enhancement: Only 26% of respondents found germline enhancement acceptable, while 51% deemed it unacceptable.
Public Views and Research Needs
A 2021 textual analysis of major agricultural stakeholder groups said further research was needed to understand perceptions of CRISPR’s agricultural applications, while noting prior work on human disease-prevention and treatment applications. A study using a national survey of 1,510 U.S. adults examines how political and religious identities relate to perceptions of scientists’ motives and how those perceptions relate to support for therapeutic gene editing. A study of public acceptance in Saudi Arabia reports that therapeutic benefit drives acceptance despite limited awareness, and that trust in national regulatory frameworks strengthens confidence in gene-therapy applications. A Nature Reviews Genetics overview notes that CRISPR-based genome-editing therapeutics are entering the clinic and reviews complementary in vitro and in vivo tools for assessing safety and efficacy.
The Path Forward: Engaging the Public in Genome Editing Decisions
The study also revealed the influence of religiosity and knowledge on attitudes toward genome editing. Those reporting low religious guidance were more supportive of both treatment and enhancement applications. Conversely, individuals with higher factual knowledge about genome editing expressed greater support for treatment applications.
Scientific Promise and Governance
A review describes how CRISPR/Cas can recognize and cut specific DNA sites among the billions of base pairs in the human genome, and discusses the possibility of repairing single-nucleotide mutations in practically any desired gene. The World Health Organization’s 2021 recommendations and governance framework offer advice on institutional, national, regional, and global mechanisms for human genome editing. WHO’s governance framework also identifies ethical issues arising from efforts to treat or prevent disease with tools such as CRISPR-Cas9, gaps in scientific understanding, and proposed applications. A separate review reports that advances in human genome editing, particularly CRISPR/Cas9, have prompted increasing ethical concerns.
Clinical Progress and Emerging Tools
A review by Ruijin Ji and colleagues surveys recent advances in CRISPR-based genome editing and its use in gene and cell therapies, emphasizing clinical progress, delivery innovations, and safety considerations. At the 2026 Genome Engineering: CRISPR Frontiers conference at Cold Spring Harbor Laboratory, researchers discussed topics ranging from bacteriophage-defense biology to clinical research using CRISPR in patients. A May 2025 industry outlook identifies next-generation CRISPR systems with improved specificity, integration with artificial intelligence for gene-editing strategies, and CRISPR-based diagnostics as emerging trends.
Public Health and Equity Questions
A public-health analysis describes CRISPR as a Nobel Prize-winning technology with promise for preventing and treating human disease, while noting that its public-health implications remain relatively uncertain and underdiscussed. It argues that targeting genetic factors alone will have limited influence on public health. Another source surveys the benefits and risks of gene-editing technologies, including medical and agricultural applications, technical limitations, regulatory approaches, and ethical considerations. Together, these sources frame CRISPR’s implications as extending beyond the editing tool itself to questions about health outcomes and how the technology is governed.
A Personalized Treatment for Infant KJ
In May 2025, Children’s Hospital of Philadelphia and Penn Medicine reported treating an infant known as KJ with a customized CRISPR gene-editing therapy for a rare metabolic disease. The institutions described the case as the world’s first patient treated with personalized CRISPR gene-editing therapy. The report presents the treatment as a landmark example of customized gene editing for a patient with a rare genetic disorder.
Interestingly, both highly religious and highly knowledgeable respondents showed strong support for public engagement in genome editing decisions. Approximately three-quarters of both groups agreed that the scientific community should consult with the public before applying gene editing technologies.
These findings underscore the importance of fostering open and inclusive dialogues about genome editing. By engaging the public, scientists and policymakers can ensure that ethical, social, and moral considerations are integrated into the development and regulation of this powerful technology. Moving forward, it is crucial to bridge the gap between scientific advancements and public understanding to promote responsible innovation in the field of human genome editing.